LEXINGTON, Mass., Oct. 23, 2018 /PRNewswire/ -- Curis, Inc.
(NASDAQ: CRIS), a biotechnology company focused on the development
and commercialization of innovative therapeutics for the treatment
of cancer, today announced that the Company will release its third
quarter 2018 financial results on Thursday,
November 1, 2018, before the U.S. financial markets open.
The Company's management will also host a conference call on the
same day at 8:30 a.m. ET.
To access the live conference call, please dial (888) 346-6389
from the United States or (412)
317-5252 from other locations, shortly before 8:30 a.m. ET. The conference call can also be
accessed on the Curis website at www.curis.com in the 'Investors'
section. A replay of the financial results conference call will be
available on the Curis website shortly after completion of the
call.
About Curis, Inc.
Curis is a biotechnology company
focused on the development and commercialization of innovative
therapeutics for the treatment of cancer, including fimepinostat,
which is being investigated in clinical studies in patients with
DLBCL and solid tumors. Curis is also engaged in a collaboration
with Aurigene in the areas of immuno-oncology and precision
oncology. As part of this collaboration, Curis has exclusive
licenses to oral small molecule antagonists of immune checkpoints
including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1
antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948.
CA-170 is currently undergoing testing in a Phase 1 trial in
patients with advanced solid tumors and lymphomas, and in a Phase 2
trial in India conducted by
Aurigene. CA-4948 is currently undergoing testing in a Phase 1
trial in patients with non-Hodgkin lymphoma. Curis is also party to
a collaboration with Genentech, a member of the Roche Group, under
which Genentech and Roche are commercializing Erivedge® for the
treatment of advanced basal cell carcinoma. For more information,
visit Curis's website at www.curis.com.
View original
content:http://www.prnewswire.com/news-releases/curis-to-release-third-quarter-financial-results-and-hold-conference-call-on-november-1-2018-300736531.html
SOURCE Curis, Inc.